Alexander A. Boucher

Alexander A. Boucher

Auto-generated profile, based on publicly available information

Alexander A. Boucher

Division of Pediatric Hematology and Oncology, Department of Pediatrics University of Minnesota Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ABAlexander A. Boucher
Alexander A. Boucher
WMWeston Miller
Weston Miller
RSRyan Shanley
Ryan Shanley
RZRichard Ziegler
Richard Ziegler
TLTroy Lund
Troy Lund
POPaul Orchard
Paul Orchard
Metachromatic Leukodystrophy (MLD) is a rare, fatal demyelinating disorder with limited treatment options. Published outcomes after hematopoietic stem cell transplantation (HSCT) are scant and mixed. We report survival and function following HSCT for a large, single-center MLD cohort. Transplant-related data, survival and serial measures (brain MRI, nerve conduction velocity (NCV), neurologic and neuropsychology evaluations) were reviewed. When possible, parental interviews informed current neurologic status, quality-of-life, and adaptive functioning. Gross motor and expressive functions for late-infantile (LI-MLD) and juvenile (J-MLD) patients were described using previously reported, MLD-specific scales. Forty patients with confirmed MLD have undergone HSCT at our center. Twenty-one (53 %) survive at a median 12 years post-HSCT. Most deaths (n = 17) were treatment-related; two died from disease progression. Survival did not depend upon MLD subtype or symptom status at transplant. LI-MLD patients survive beyond reported life expectancy in untreated disease. Abnormal brain MRI and peripheral nerve conduction velocities (NCV) were common before HSCT. Following transplant, fewer patients experienced MRI progression compared to NCV deterioration. Sixteen LI-MLD and J-MLD survivors were evaluable for long-term gross motor and/or expressive language functioning using existing MLD clinical scoring systems. While most J-MLD patients regressed, the aggregate cohort demonstrated superior retention of function compared to published natural history. Seventeen LI-MLD, J-MLD and adult subtype (A-MLD) survivors were evaluable for long-term adaptive functioning, activities of daily living, and/or cognition. Relative cognitive sparing was observed despite overall global decline. Five sibling pairs (one LI-MLD and four J-MLD), in which at least one underwent transplant in our cohort, were evaluable. Within each familial dyad, survival or function was superior for the treated sibling, or if both siblings were transplanted, for the pre-symptomatic sibling. HSCT is a viable treatment option for MLD, but has significant limitations. Later-onset phenotypes may benefit most from early, pre-symptomatic transplant. Until superior, novel treatment strategies are demonstrated, MLD patients should be carefully considered for HSCT.

1 October 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AGArun Gurunathan
Arun Gurunathan
ABAlexander A. Boucher
Alexander A. Boucher
MMMelissa Mark
Melissa Mark
KPKristina M. Prus
Kristina M. Prus
MOMaureen M. O'BRien
Maureen M. O'BRien
AKAshish R. Kumar
Ashish R. Kumar

25 January 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ABAlexander A. Boucher
Alexander A. Boucher
APAmanda Pfeiffer
Amanda Pfeiffer
ABAshley Bedel
Ashley Bedel
JYJennifer Young
Jennifer Young
PMPatrick T. McGann
Patrick T. McGann

26 March 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ABAlexander A. Boucher
Alexander A. Boucher
ABAshley Bedel
Ashley Bedel
SJSommer Jones
Sommer Jones
SLStephanie F. Lenahan
Stephanie F. Lenahan
RGRebecca Geer
Rebecca Geer
PMPatrick T. McGann
Patrick T. McGann

20 September 2019 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ABAlexander A. Boucher
Alexander A. Boucher
LRLeah Rosenfeldt
Leah Rosenfeldt
DMDuaa Mureb
Duaa Mureb
JSJessica Shafer
Jessica Shafer
BSBal Krishan Sharma
Bal Krishan Sharma
JPJoseph S. Palumbo
Joseph S. Palumbo

14 June 2022 in Frontiers in Surgery
Verified
Journal Article
Open access
ABAlexander A. Boucher
Alexander A. Boucher
JHJulia A. Heneghan
Julia A. Heneghan
SJSubin Jang
Subin Jang
KSKaitlyn A. Spillane
Kaitlyn A. Spillane
AAAaron M. Abarbanell
Aaron M. Abarbanell
AMAndrew D. Meyer
Andrew D. Meyer
Congenital heart disease encompasses a range of cardiac birth defects. Some defects require early and complex surgical intervention and post-operative thromboprophylaxis primarily for valve, conduit, and shunt patency. Antiplatelet and anticoagulant management strategies vary considerably and may or may not align with recognized consensus practice guidelines. In addition, newer anticoagulant agents are being increasingly used in children, but these medications are not addressed in most consensus statements.This narrative review evaluated the literature from 2011 through 2021 on the topic of postoperative thromboprophylaxis after congenital heart disease operations. The search was focused on the descriptions and results of pediatric studies for replacement and/or repair of heart valves, shunts, conduits, and other congenital heart disease operations. Wide variability in practice exists and, as was true a decade ago, few randomized controlled trials have been conducted. Aspirin, warfarin, and perioperative heparin remain the most commonly used agents with varying dosing, duration, and monitoring strategies, making comparisons difficult. Only recently have data on direct oral anticoagulants been published in children, suggesting evolving paradigms of care. Our findings highlight the need for more research to strengthen the evidence for standardized thromboprophylaxis strategies.